atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

“From the thousand-foot level, there hasn’t been really meaningful advancement in psychiatry, at least in the depression space, since the 1980s with SSRIs,” Glenn Short, PhD, senior vice president of Early Development at atai Life Sciences, told GEN Edge. “There is certainly a need for rapidly acting antidepressants that are clinically meaningful. So, I do see that psychedelics fit that niche pretty readily.”

atai Life Sciences N.V., a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the initiation of its Phase 2b proof-of-concept clinical trial for RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS), a condition for which there are currently no FDA-approved treatments.

An atai Life Sciences hosted event featuring a presentation by Key Opinion Leader (KOL) Richard S.E. Keefe, PhD, of Duke University.

Dr. Keefe discussed the current treatment landscape and unmet medical need in treating patients with Cognitive Impairment Associated with Schizophrenia (CIAS), followed by Matthew Pando, PhD, CEO and Co-Founder of Recognify Life Sciences, who discussed the design of the completed Phase 2a trial for RL-007 and the preliminary topline data.

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced positive topline data from its Phase 2a study of RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS).

Recognify Life Sciences, an atai Life Sciences platform company focused on developing treatments for cognitive impairment with initial efforts targeting Cognitive Impairment Associated with Schizophrenia (CIAS), today announced it has initiated a Phase 2a study for its lead compound RL-007, after receiving IND clearance from the Food and Drug Administration to commence clinical trials in the United States in this indication

Atai announced that it has acquired a majority stake in Recognify Life Sciences ("Recognify"), an entity developing a treatment for Cognitive Impairment associated with Schizophrenia ("CIAS").